Entelos, Inc. has announced a publication in the peer-reviewed journal Clinical and Experimental Immunology describing the Type 1 Diabetes (T1D) PhysioLab® platform, an in silico solution for rapidly streamlining preclinical research through the evaluation of alternative scenarios for therapeutic strategies. Access to a version of the T1D PhysioLab platform is provided by Clinical and Experimental Immunology through supplemental information described in the journal, allowing readers to navigate through the platform to learn about its features and capabilities.
“The platform provides a better understanding of the progression of T1D across multiple disease stages, and focuses on disease prevention and remission, not disease management.”
T1D, also known as juvenile-onset or insulin-dependent diabetes, is an autoimmune disease and a metabolic disorder characterized by immune-mediated destruction of pancreatic beta cells, resulting in insulin deficiency and hyperglycaemia. It affects over 400,000 children worldwide, with a reported annual global increase of about 3%. T1D can lead to complications such as cardiovascular disease, renal disease, diabetic retinopathy and peripheral neuropathy, and may even lead to coma and death. There is currently no cure for T1D.
"In silico research in the T1D PhysioLab platform rapidly provides investigators with testable predictions and recommendations," stated Thomas Paterson, CTO and Co-Founder at Entelos. "The platform provides a better understanding of the progression of T1D across multiple disease stages, and focuses on disease prevention and remission, not disease management."
The T1D PhysioLab platform reproduces key disease features including activation and expansion of autoreactive T and B cells, islet infiltration, and beta cell loss that leads to hyperglycemia. Simulated disease outcomes for interventions such as rapamycin, transforming growth factor (TGF)-beta, exendin-4, and others compare well with published experimental data.
SOURCE Entelos, Inc.